

Editorial

Implication of Oxysterols in Infectious and Non-Communicable Inflammatory Diseases

G rard Lizard ^{1,*} , John J. Mackrill ²  and Tim Willinger ³ 

¹ Team “Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism”, Universit  de Bourgogne Franche-Comt /Inserm, 21000 Dijon, France

² Department of Physiology, School of Medicine, University College Cork, Western Gateway Building, Western Road, T12 XF62 Cork, Ireland

³ Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, 141 52 Stockholm, Sweden

* Correspondence: gerard.lizard@u-bourgogne.fr; Tel.: +33-3-8039-6256; Fax: +33-3-8039-6250

Oxysterols, derived from cholesterol oxidation, are formed either by autoxidation, via enzymes, or by both processes [1,2]. These molecules have multiple biological activities and can regulate oxidative stress, inflammation, cell death, as well as cell differentiation and cholesterol homeostasis [3–5]. At the cellular level, depending on their structures, oxysterols can act at the level of the plasma membrane, endoplasmic reticulum, organelles (mitochondria, peroxisome and lysosome) and/or at the nuclear level. Several of these oxysterols, in particular those resulting from the oxidation of cholesterol on its side chain, can be ligands or activators of the following receptors: (i) nuclear receptors, such as liver X receptors (LXRs) α or β [6] and retinoic acid receptor-related orphan receptor α and γ (ROR α [NR1F1] and ROR γ [NR1F3]) [7], but also (ii) cytoplasmic receptors such as SREBP (sterol regulatory element binding transcription protein) [8], NPC1 (NPC intracellular cholesterol transporter 1 / Nieman-Pick type C1) [9], FXR (NR1H4, farnesoid X receptor alpha) [10], oxysterols binding proteins (OSBPs), OSBPs-related proteins (ORPs) [11,12] and cholesterol epoxide hydrolase (ChEH) (also named anti-estrogen binding site (AEBS); ChEH is a hetero-oligomeric complex comprising 3beta-hydroxysterol-delta(8)-delta(7)-isomerase (D8D7I) and 3beta-hydroxysterol-delta(7)-reductase (DHCR7)) [13] as well as (iii) membrane receptors such as receptor tyrosine kinases [14] and the Epstein–Barr virus-induced gene 2 receptor (EBI2, also known as GPR183) [15–17]. Some of these receptors are involved in the control of cholesterol trafficking, cell proliferation, and cell death. For the receptors (RORs, FXR, LXRs, EBI2), there are several lines of evidence for their involvement in inflammation [18–21]. Other oxysterols oxidized at C7, such as 7-ketocholesterol (7KC) and 7 β -hydroxycholesterol, which either minimally or do not interact with these receptors, are potent inducers of inflammation and are known to have an important role in the pathophysiology of many age-related diseases (cardiovascular, ocular and neurodegenerative diseases) [3,22]. These C7-oxidized oxysterols trigger both the production of inflammatory cytokines [23] and prostaglandins [24,25]. Prostacyclin (PGI₂) production, which promotes platelet aggregation, has also been described in 7KC-treated endothelial cells [26]. The ability of 7KC to induce inflammation is likely to occur mainly through the TLR4 receptor both in vitro and in vivo [27].

To date, the pro-inflammatory activities of oxysterols are thought to be involved in chronic inflammatory diseases (cardiovascular diseases, inflammatory bowel disease), as well as in common (multiple sclerosis, Alzheimer’s disease) and rare neurodegenerative diseases, such as X-linked adrenoleukodystrophy (X-ALD) [22,28–30]. Certain oxysterols can also act on bacteria, viruses, and parasites [31–33]. Thus, several oxysterols are involved in the immune response and can act on infectious agents [34]; their involvement in the immune response and cytokine storm is very likely, because some of their receptors are associated with immune activities and signaling pathways by which oxysterols



Citation: Lizard, G.; Mackrill, J.J.; Willinger, T. Implication of Oxysterols in Infectious and Non-Communicable Inflammatory Diseases. *Cells* **2023**, *12*, 241. <https://doi.org/10.3390/cells12020241>

Received: 21 December 2022

Accepted: 30 December 2022

Published: 6 January 2023



Copyright:   2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

promote cytokine production. The aim of this Special Issue is to cover these different aspects as well as pharmacological studies on the molecules that modulate the biological activities of oxysterols in both infectious and non-communicable inflammatory diseases. This Special Issue entitled “Oxysterols and the Immune Response: Implications in Non-communicable and Infectious Diseases” was supervised by three Guest Editors: Dr John Mackrill (University College of Cork, Cork, Ireland), Dr Tim Willinger (Karolinska Institutet, Stockholm, Sweden) and Dr Gérard Lizard (University of Burgundy/Inserm, Dijon, France). Five publications are associated with this Special Issue including three reviews and two research papers.

The review by Fabio Alessandro de Freitas et al. [35] focuses in particular on 25-hydroxycholesterol and 7 α ,25-dihydroxycholesterol in the immune system and related diseases. The effects of these oxysterols and the LXRs and EBI2 receptors are discussed in the context of the immune response in the blood and central nervous system. The implication of these oxysterols in several chronic inflammatory diseases and certain cancers are also presented. The review by Cheng Xiang Foo et al. [36] covers the state of knowledge regarding oxysterols and their effect on the control of intracellular bacterial growth as well as viral entry into the host cells and viral replication. The review by Lisa Reinmuth et al. [37] surveys the two broad classes of cell-surface receptors for oxysterols (G protein-coupled receptors and ion channels), the mechanisms by which oxysterols act on them, and their functions in the different cell types of the immune system. In addition, Line Barington et al. [38] showed that GPR183/EBI2 is unnecessary for B1 cell accumulation and function, but affects B2 cell abundance, in the omentum (fatty tissue, part of the peritoneum, connecting stomach, intestine and colon) and peritoneal cavity. Furthermore, when human brain endothelial cells (hCMEC/D3) were cultured in the presence of 7KC, an increase in the expression of pro-inflammatory cytokines (IL-1 β , IL-6, IL-8 and TNF- α) was observed as well as an increase in the expression of cyclo-oxygenase-2 (COX-2) which catalyzes the conversion of arachidonic acid to prostaglandins [39]. In the presence of withanolide A, a naturally occurring phytochemical that is found in Ashwagandha (*Withania somnifera*, fam. Solanaceae) and Indian Ginseng, the pro-inflammatory effects of 7KC were strongly and significantly reduced as well as its pro-oxidative effects associated with cell death induction [40].

This Special Issue of Cells, therefore, presents several works that provide information to better understand the pro-inflammatory effects of several oxysterols and some of their associated receptors, both in the context of infectious diseases and chronic inflammatory diseases with potential pharmacological applications.

Author Contributions: Conceptualization, G.L.; writing—review and editing, G.L., J.J.M. and T.W.; supervision, G.L.; project administration, G.L. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by Université de Bourgogne and Inserm.

Acknowledgments: The authors thank the European Network for Oxysterol Research (ENOR; <https://www.oxysterols.net/>), founding members: Gérard Lizard and Luigi Iuliano; accessed on 5 January 2023) which contributed to collaboration between the authors.

Conflicts of Interest: The authors have no conflict of interest to declare.

References

1. Mutemberezi, V.; Guillemot-Legrès, O.; Muccioli, G.G. Oxysterols: From cholesterol metabolites to key mediators. *Prog. Lipid Res.* **2016**, *64*, 152–169. [CrossRef] [PubMed]
2. Ghzaïel, I.S.K.; Zarrouk, A.; Ghosh, S.; Dias, I.H.K.; Nury, T.; Ksila, M.; Essadek, S.; Tahri Joutey, M.; Brahmi, F.; Mihoubi, W.; et al. Sources of 7-ketocholesterol, metabolism and inactivation strategies: Food and biomedical applications. *Redox Exp. Med.* **2022**, *1*, R40–R46. [CrossRef]
3. Vejux, A.; Lizard, G. Cytotoxic effects of oxysterols associated with human diseases: Induction of cell death (apoptosis and/or oncosis), oxidative and inflammatory activities, and phospholipidosis. *Mol. Asp. Med.* **2009**, *30*, 153–170. [CrossRef] [PubMed]

4. Griffiths, W.J.; Wang, Y. Sterols, Oxysterols, and Accessible Cholesterol: Signalling for Homeostasis, in Immunity and during Development. *Front. Physiol.* **2021**, *12*, 1688. [\[CrossRef\]](#) [\[PubMed\]](#)
5. de Freitas, F.A.; Levy, D.; Zarrouk, A.; Lizard, G.; Bydlowski, S.P. Impact of Oxysterols on Cell Death, Proliferation, and Differentiation Induction: Current Status. *Cells* **2021**, *10*, 2301. [\[CrossRef\]](#)
6. Viennois, E.; Pommier, A.J.; Mouzat, K.; Oumeddour, A.; El Hajjaji, F.Z.; Dufour, J.; Caira, F.; Volle, D.H.; Baron, S.; Lobaccaro, J.M. Targeting liver X receptors in human health: Deadlock or promising trail? *Expert Opin. Ther. Targets* **2011**, *15*, 219–232. [\[CrossRef\]](#)
7. Wang, Y.; Kumar, N.; Crumbley, C.; Griffin, P.R.; Burris, T.P. A second class of nuclear receptors for oxysterols: Regulation of RORalpha and RORgamma activity by 24S-hydroxycholesterol (cerebrosterol). *Biochim. Biophys. Acta* **2010**, *1801*, 917–923. [\[CrossRef\]](#)
8. Sato, R. Sterol metabolism and SREBP activation. *Arch. Biochem. Biophys.* **2010**, *501*, 177–181. [\[CrossRef\]](#)
9. Yu, X.H.; Jiang, N.; Yao, P.B.; Zheng, X.L.; Cayabyab, F.S.; Tang, C.K. NPC1, intracellular cholesterol trafficking and atherosclerosis. *Clin. Chim. Acta* **2014**, *429*, 69–75. [\[CrossRef\]](#)
10. Kovač, U.; Skubic, C.; Bohinc, L.; Rozman, D.; Režen, T. Oxysterols and Gastrointestinal Cancers Around the Clock. *Front. Endocrinol.* **2019**, *10*, 483. [\[CrossRef\]](#)
11. Olkkonen, V.M.; Ikonen, E. Cholesterol transport in the late endocytic pathway: Roles of ORP family proteins. *J. Steroid Biochem. Mol. Biol.* **2022**, *216*, 106040. [\[CrossRef\]](#) [\[PubMed\]](#)
12. Arora, A.; Taskinen, J.H.; Olkkonen, V.M. Coordination of inter-organelle communication and lipid fluxes by OSBP-related proteins. *Prog. Lipid Res.* **2022**, *86*, 101146. [\[CrossRef\]](#)
13. Silvente-Poirot, S.; Poirot, M. Cholesterol epoxide hydrolase and cancer. *Curr. Opin. Pharmacol.* **2012**, *12*, 696–703. [\[CrossRef\]](#) [\[PubMed\]](#)
14. Kim, Y.J.; Lee, C.S. Tyrosine kinase inhibitor AG126 reduces 7-ketocholesterol-induced cell death by suppressing mitochondria-mediated apoptotic process. *Neurochem. Res.* **2010**, *35*, 603–612. [\[CrossRef\]](#) [\[PubMed\]](#)
15. Hannedouche, S.; Zhang, J.; Yi, T.; Shen, W.; Nguyen, D.; Pereira, J.P.; Guerini, D.; Baumgarten, B.U.; Roggo, S.; Wen, B.; et al. Oxysterols direct immune cell migration via EBI2. *Nature* **2011**, *475*, 524–527. [\[CrossRef\]](#) [\[PubMed\]](#)
16. Liu, C.; Yang, X.V.; Wu, J.; Kuei, C.; Mani, N.S.; Zhang, L.; Yu, J.; Sutton, S.W.; Qin, N.; Banie, H.; et al. Oxysterols direct B-cell migration through EBI2. *Nature* **2011**, *475*, 519–523. [\[CrossRef\]](#) [\[PubMed\]](#)
17. Emgård, J.; Kammoun, H.; García-Cassani, B.; Chesné, J.; Parigi, S.M.; Jacob, J.M.; Cheng, H.W.; Evren, E.; Das, S.; Czarnewski, P.; et al. Oxysterol Sensing through the Receptor GPR183 Promotes the Lymphoid-Tissue-Inducing Function of Innate Lymphoid Cells and Colonic Inflammation. *Immunity* **2018**, *48*, 120–132.e128. [\[CrossRef\]](#)
18. Spann, N.J.; Glass, C.K. Sterols and oxysterols in immune cell function. *Nat. Immunol.* **2013**, *14*, 893–900. [\[CrossRef\]](#)
19. Pascual-García, M.; Valledor, A.F. Biological roles of liver X receptors in immune cells. *Arch. Immunol. Ther. Exp.* **2012**, *60*, 235–249. [\[CrossRef\]](#)
20. Fessler, M.B. The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease. *Pharmacol. Ther.* **2018**, *181*, 1–12. [\[CrossRef\]](#)
21. Cariello, M.; Piccinin, E.; Moschetta, A. Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH. *Cell. Mol. Gastroenterol. Hepatol.* **2021**, *11*, 1519–1539. [\[CrossRef\]](#) [\[PubMed\]](#)
22. Zarrouk, A.; Vejux, A.; Mackrill, J.; O’Callaghan, Y.; Hammami, M.; O’Brien, N.; Lizard, G. Involvement of oxysterols in age-related diseases and ageing processes. *Ageing Res. Rev.* **2014**, *18*, 148–162. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Prunet, C.; Montange, T.; Vejux, A.; Laubriet, A.; Rohmer, J.F.; Riedinger, J.M.; Athias, A.; Lemaire-Ewing, S.; Néel, D.; Petit, J.M.; et al. Multiplexed flow cytometric analyses of pro- and anti-inflammatory cytokines in the culture media of oxysterol-treated human monocytic cells and in the sera of atherosclerotic patients. *Cytometry A* **2006**, *69*, 359–373. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Tesoriere, L.; Attanzio, A.; Allegra, M.; Cilla, A.; Gentile, C.; Livrea, M.A. Oxysterol mixture in hypercholesterolemia-relevant proportion causes oxidative stress-dependent eryptosis. *Cell. Physiol. Biochem.* **2014**, *34*, 1075–1089. [\[CrossRef\]](#)
25. Watanabe, Y.; Yamaguchi, T.; Ishihara, N.; Nakamura, S.; Tanaka, S.; Oka, R.; Imamura, H.; Sato, Y.; Ban, N.; Kawana, H.; et al. 7-Ketocholesterol induces ROS-mediated mRNA expression of 12-lipoxygenase, cyclooxygenase-2 and pro-inflammatory cytokines in human mesangial cells: Potential role in diabetic nephropathy. *Prostaglandins Other Lipid Mediat.* **2018**, *134*, 16–23. [\[CrossRef\]](#) [\[PubMed\]](#)
26. Peng, S.K.; Hu, B.; Peng, A.Y.; Morin, R.J. Effect of cholesterol oxides on prostacyclin production and platelet adhesion. *Artery* **1993**, *20*, 122–134.
27. Huang, J.D.; Amaral, J.; Lee, J.W.; Rodriguez, I.R. 7-Ketocholesterol-induced inflammation signals mostly through the TLR4 receptor both in vitro and in vivo. *PLoS ONE* **2014**, *9*, e100985. [\[CrossRef\]](#)
28. Nury, T.; Zarrouk, A.; Ragot, K.; Debbabi, M.; Riedinger, J.M.; Vejux, A.; Aubourg, P.; Lizard, G. 7-Ketocholesterol is increased in the plasma of X-ALD patients and induces peroxisomal modifications in microglial cells: Potential roles of 7-ketocholesterol in the pathophysiology of X-ALD. *J. Steroid Biochem. Mol. Biol.* **2017**, *169*, 123–136. [\[CrossRef\]](#)
29. Testa, G.; Rossin, D.; Poli, G.; Biasi, F.; Leonarduzzi, G. Implication of oxysterols in chronic inflammatory human diseases. *Biochimie* **2018**, *153*, 220–231. [\[CrossRef\]](#)
30. Willinger, T. Oxysterols in intestinal immunity and inflammation. *J. Intern. Med.* **2019**, *285*, 367–380. [\[CrossRef\]](#)
31. Lembo, D.; Cagno, V.; Civra, A.; Poli, G. Oxysterols: An emerging class of broad spectrum antiviral effectors. *Mol. Asp. Med.* **2016**, *49*, 23–30. [\[CrossRef\]](#) [\[PubMed\]](#)
32. Vale, N.; Gouveia, M.J.; Gärtner, F.; Brindley, P.J. Oxysterols of helminth parasites and pathogenesis of foodborne hepatic trematodiasis caused by *Opisthorchis* and *Fasciola* species. *Parasitol. Res.* **2020**, *119*, 1443–1453. [\[CrossRef\]](#) [\[PubMed\]](#)

33. Ghzaïel, I.; Sassi, K.; Zarrouk, A.; Nury, T.; Ksila, M.; Leoni, V.; Bouhaouala-Zahar, B.; Hammami, S.; Hammami, M.; Mackrill, J.J.; et al. 7-Ketocholesterol: Effects on viral infections and hypothetical contribution in COVID-19. *J. Steroid Biochem. Mol. Biol.* **2021**, *212*, 105939. [[CrossRef](#)] [[PubMed](#)]
34. Bah, S.Y.; Dickinson, P.; Forster, T.; Kampmann, B.; Ghazal, P. Immune oxysterols: Role in mycobacterial infection and inflammation. *J. Steroid Biochem. Mol. Biol.* **2017**, *169*, 152–163. [[CrossRef](#)]
35. de Freitas, F.A.; Levy, D.; Reichert, C.O.; Cunha-Neto, E.; Kalil, J.; Bydlowski, S.P. Effects of Oxysterols on Immune Cells and Related Diseases. *Cells* **2022**, *11*, 1251. [[CrossRef](#)] [[PubMed](#)]
36. Foo, C.X.; Bartlett, S.; Ronacher, K. Oxysterols in the Immune Response to Bacterial and Viral Infections. *Cells* **2022**, *11*, 201. [[CrossRef](#)]
37. Reinmuth, L.; Hsiao, C.C.; Hamann, J.; Rosenkilde, M.; Mackrill, J. Multiple Targets for Oxysterols in Their Regulation of the Immune System. *Cells* **2021**, *10*, 2078. [[CrossRef](#)]
38. Barington, L.; Christensen, L.V.V.; Pedersen, K.K.; Niss Arfelt, K.; Roumain, M.; Jensen, K.H.R.; Kjær, V.M.S.; Daugvilaite, V.; Kearney, J.F.; Christensen, J.P.; et al. GPR183 Is Dispensable for B1 Cell Accumulation and Function, but Affects B2 Cell Abundance, in the Omentum and Peritoneal Cavity. *Cells* **2022**, *11*, 494. [[CrossRef](#)]
39. Kam, P.C.; See, A.U. Cyclo-oxygenase isoenzymes: Physiological and pharmacological role. *Anaesthesia* **2000**, *55*, 442–449. [[CrossRef](#)]
40. Soh, S.; Ong, W.Y. Effect of Withanolide A on 7-Ketocholesterol Induced Cytotoxicity in hCMEC/D3 Brain Endothelial Cells. *Cells* **2022**, *11*, 457. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.